rg3039 Search Results


rg3039  (MedChemExpress)
93
MedChemExpress rg3039
Targeting DCPS suppressed proliferation and colony formation and induced apoptosis of GBM cells ( a ) GBM cell lines were transfected with siRNA targeting DCPS. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( b ) GBM cell lines were treated with various concentrations of <t>RG3039</t> or DMSO. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( c ) Representative images of colony formation of GBM cell lines treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells treated with RG3039 to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( e ) Quantified data of Annexin-V-positive cells in apoptosis assays (see Figure a for details) in GBM cell lines treated with specific concentrations of RG3039 or DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( f ) GBM cell lines were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3)
Rg3039, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rg3039/product/MedChemExpress
Average 93 stars, based on 1 article reviews
rg3039 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
compound rg3039  (Vertex Pharmaceuticals)
90
Vertex Pharmaceuticals compound rg3039
Targeting DCPS suppressed proliferation and colony formation and induced apoptosis of GBM cells ( a ) GBM cell lines were transfected with siRNA targeting DCPS. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( b ) GBM cell lines were treated with various concentrations of <t>RG3039</t> or DMSO. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( c ) Representative images of colony formation of GBM cell lines treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells treated with RG3039 to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( e ) Quantified data of Annexin-V-positive cells in apoptosis assays (see Figure a for details) in GBM cell lines treated with specific concentrations of RG3039 or DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( f ) GBM cell lines were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3)
Compound Rg3039, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound rg3039/product/Vertex Pharmaceuticals
Average 90 stars, based on 1 article reviews
compound rg3039 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
rg3039  (Pfizer Inc)
90
Pfizer Inc rg3039
Targeting DCPS suppressed proliferation and colony formation and induced apoptosis of GBM cells ( a ) GBM cell lines were transfected with siRNA targeting DCPS. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( b ) GBM cell lines were treated with various concentrations of <t>RG3039</t> or DMSO. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( c ) Representative images of colony formation of GBM cell lines treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells treated with RG3039 to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( e ) Quantified data of Annexin-V-positive cells in apoptosis assays (see Figure a for details) in GBM cell lines treated with specific concentrations of RG3039 or DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( f ) GBM cell lines were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3)
Rg3039, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rg3039/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
rg3039 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
rg3039  (Karebay Inc)
90
Karebay Inc rg3039
Targeting DCPS suppressed proliferation and colony formation and induced apoptosis of GBM cells ( a ) GBM cell lines were transfected with siRNA targeting DCPS. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( b ) GBM cell lines were treated with various concentrations of <t>RG3039</t> or DMSO. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( c ) Representative images of colony formation of GBM cell lines treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells treated with RG3039 to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( e ) Quantified data of Annexin-V-positive cells in apoptosis assays (see Figure a for details) in GBM cell lines treated with specific concentrations of RG3039 or DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( f ) GBM cell lines were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3)
Rg3039, supplied by Karebay Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rg3039/product/Karebay Inc
Average 90 stars, based on 1 article reviews
rg3039 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Targeting DCPS suppressed proliferation and colony formation and induced apoptosis of GBM cells ( a ) GBM cell lines were transfected with siRNA targeting DCPS. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( b ) GBM cell lines were treated with various concentrations of RG3039 or DMSO. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( c ) Representative images of colony formation of GBM cell lines treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells treated with RG3039 to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( e ) Quantified data of Annexin-V-positive cells in apoptosis assays (see Figure a for details) in GBM cell lines treated with specific concentrations of RG3039 or DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( f ) GBM cell lines were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3)

Journal: Journal of Translational Medicine

Article Title: Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma

doi: 10.1186/s12967-024-05658-x

Figure Lengend Snippet: Targeting DCPS suppressed proliferation and colony formation and induced apoptosis of GBM cells ( a ) GBM cell lines were transfected with siRNA targeting DCPS. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( b ) GBM cell lines were treated with various concentrations of RG3039 or DMSO. Cell proliferation was monitored by CCK-8 assay for 120 h. Quantification of the fold change of the OD450 value at each time point compared with that at 0 h (mean ± SEM, n = 3) ( c ) Representative images of colony formation of GBM cell lines treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells treated with RG3039 to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( e ) Quantified data of Annexin-V-positive cells in apoptosis assays (see Figure a for details) in GBM cell lines treated with specific concentrations of RG3039 or DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, **, p < 0.01, ***, p < 0.001 ( f ) GBM cell lines were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3)

Article Snippet: To measure the growth of GBOs, similarly sized GBOs (0.5–1 mm diameter) were placed into individual wells of a 48-well tissue culture plate with 300 mL of GBO medium containing 10 µM RG3039 (HY-102020, MedChemExpress) or solvent (DMSO) per well.

Techniques: Transfection, CCK-8 Assay

The anti-GBM effects of RG3039 on patient-derived GBM organoids (GBOs) ( a – b ) Growth of GBOs treated with RG3039 (10 µM) or DMSO for 15 days ( a ) Representative bright-field images of GBOs. Scale bar, 250 μm. ( b ) Quantification of the ratio of the 2D area at each time point to that at day 0 for the same GBOs (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001 ( c ) Representative images of H&E staining and IHC staining for Ki67 of GBOs treated with RG3039 (8 µM, 16 µM, or 32 µM) or DMSO for 48 h. Scale bar, 250 μm ( d ) Quantification of Ki67 − positive cell density in GBOs treated with RG3039 (8 µM, 16 µM, or 32 µM) or DMSO in IHC staining (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance ( e ) Comparison of IC50 of RG3039 and TMZ in GBOs ( n = 14). Statistical analysis by paired t-test, NS, no significance

Journal: Journal of Translational Medicine

Article Title: Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma

doi: 10.1186/s12967-024-05658-x

Figure Lengend Snippet: The anti-GBM effects of RG3039 on patient-derived GBM organoids (GBOs) ( a – b ) Growth of GBOs treated with RG3039 (10 µM) or DMSO for 15 days ( a ) Representative bright-field images of GBOs. Scale bar, 250 μm. ( b ) Quantification of the ratio of the 2D area at each time point to that at day 0 for the same GBOs (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001 ( c ) Representative images of H&E staining and IHC staining for Ki67 of GBOs treated with RG3039 (8 µM, 16 µM, or 32 µM) or DMSO for 48 h. Scale bar, 250 μm ( d ) Quantification of Ki67 − positive cell density in GBOs treated with RG3039 (8 µM, 16 µM, or 32 µM) or DMSO in IHC staining (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance ( e ) Comparison of IC50 of RG3039 and TMZ in GBOs ( n = 14). Statistical analysis by paired t-test, NS, no significance

Article Snippet: To measure the growth of GBOs, similarly sized GBOs (0.5–1 mm diameter) were placed into individual wells of a 48-well tissue culture plate with 300 mL of GBO medium containing 10 µM RG3039 (HY-102020, MedChemExpress) or solvent (DMSO) per well.

Techniques: Derivative Assay, Staining, Immunohistochemistry, Comparison

The anti-GBM effect of RG3039 in orthotopic GBM mouse model ( a – d ) GBM was induced by orthotopic implantation with U251 cells in BALB/c nude mice, and mice were treated with RG3039 ( n = 6), TMZ ( n = 10) or DMSO ( n = 10) ( a ) Mouse survival was monitored and data were subjected to two-sided log-rank Mantel–Cox analysis( n = 6 for RG3039 group, n = 10 for TMZ group and n = 10 for DMSO group). MS, median survival, NS, no significance, **, p < 0.01 ( b ) Fold change of tumor growth was analyzed by bioluminescence imaging 14 days after treatment (mean ± SEM, n = 6 for RG3039 group, n = 10 for TMZ group and n = 10 for DMSO group) ( c ) Representative images of tumor volume measured by bioluminescence at day 14 after treatment ( d ) Quantification of tumor volume measured by bioluminescence imaging at day 14 after treatment (mean ± SEM, n = 6 for RG3039 group, n = 10 for TMZ group and n = 10 for DMSO group). Statistical analysis by unpaired t-test, NS, no significance, **, p < 0.01 ( e – h ) GBM was induced by orthotopic implantation of U87 cells in BALB/c nude mice, and mice were treated with RG3039 ( n = 10) or DMSO ( n = 8) ( e ) Mouse survival was monitored and data were subjected to two-sided log-rank Mantel–Cox analysis ( n = 10 for RG3039 group and n = 8 for DMSO group). MS, median survival, NS, no significance, *, p < 0.05 ( f ) Fold change of tumor growth was analyzed by bioluminescence imaging 10 days after treatment (mean ± SEM, n = 10 for RG3039 group and n = 8 for DMSO group) ( g ) Representative images of tumor volume measured by bioluminescence at day 10 after treatment ( h ) Quantification of tumor volume measured by bioluminescence imaging at day 10 after treatment (mean ± SEM, n = 10 for RG3039 group and n = 8 for DMSO group). Statistical analysis by unpaired t-test, *, p < 0.05

Journal: Journal of Translational Medicine

Article Title: Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma

doi: 10.1186/s12967-024-05658-x

Figure Lengend Snippet: The anti-GBM effect of RG3039 in orthotopic GBM mouse model ( a – d ) GBM was induced by orthotopic implantation with U251 cells in BALB/c nude mice, and mice were treated with RG3039 ( n = 6), TMZ ( n = 10) or DMSO ( n = 10) ( a ) Mouse survival was monitored and data were subjected to two-sided log-rank Mantel–Cox analysis( n = 6 for RG3039 group, n = 10 for TMZ group and n = 10 for DMSO group). MS, median survival, NS, no significance, **, p < 0.01 ( b ) Fold change of tumor growth was analyzed by bioluminescence imaging 14 days after treatment (mean ± SEM, n = 6 for RG3039 group, n = 10 for TMZ group and n = 10 for DMSO group) ( c ) Representative images of tumor volume measured by bioluminescence at day 14 after treatment ( d ) Quantification of tumor volume measured by bioluminescence imaging at day 14 after treatment (mean ± SEM, n = 6 for RG3039 group, n = 10 for TMZ group and n = 10 for DMSO group). Statistical analysis by unpaired t-test, NS, no significance, **, p < 0.01 ( e – h ) GBM was induced by orthotopic implantation of U87 cells in BALB/c nude mice, and mice were treated with RG3039 ( n = 10) or DMSO ( n = 8) ( e ) Mouse survival was monitored and data were subjected to two-sided log-rank Mantel–Cox analysis ( n = 10 for RG3039 group and n = 8 for DMSO group). MS, median survival, NS, no significance, *, p < 0.05 ( f ) Fold change of tumor growth was analyzed by bioluminescence imaging 10 days after treatment (mean ± SEM, n = 10 for RG3039 group and n = 8 for DMSO group) ( g ) Representative images of tumor volume measured by bioluminescence at day 10 after treatment ( h ) Quantification of tumor volume measured by bioluminescence imaging at day 10 after treatment (mean ± SEM, n = 10 for RG3039 group and n = 8 for DMSO group). Statistical analysis by unpaired t-test, *, p < 0.05

Article Snippet: To measure the growth of GBOs, similarly sized GBOs (0.5–1 mm diameter) were placed into individual wells of a 48-well tissue culture plate with 300 mL of GBO medium containing 10 µM RG3039 (HY-102020, MedChemExpress) or solvent (DMSO) per well.

Techniques: Imaging

DCPS inhibition reduced STAT5B expression in GBM cells ( a – b ) GBM cell lines were treated with RG3039 (6 µM) or DMSO for 48 h and then subjected to RNAseq. The top 20 differentially expressed transcription factors were displayed in heatmap ( a ) and volcano plot ( b ). FC, fold change ( c ) Correlation analysis of the expressions of DCPS and STAT5B in GBMs in TCGA database. Statistical analysis by linear regression analysis ( d ) GBM cell lines were transfected with siRNA targeting DCPS for 48 h. The expression of STAT5B mRNA was analyzed by RT-qPCR and normalized to that of β-actin (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, **, p < 0.01, ***, p < 0.001 ( e ) GBM cell lines were treated with RG3039 (6 µM) or DMSO for 48 h. The expression of STAT5B mRNA was analyzed by RT-qPCR and normalized to that of β-actin (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, ****, p < 0.0001 ( f ) GBM cell lines were transfected with siRNA targeting DCPS for 48 h. The expressions of DCPS and STAT5B were analyzed by western blotting ( g ) GBM cell lines were treated with RG3039 (6 µM) or DMSO for 48 h. The expression of STAT5B was analyzed by western blotting

Journal: Journal of Translational Medicine

Article Title: Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma

doi: 10.1186/s12967-024-05658-x

Figure Lengend Snippet: DCPS inhibition reduced STAT5B expression in GBM cells ( a – b ) GBM cell lines were treated with RG3039 (6 µM) or DMSO for 48 h and then subjected to RNAseq. The top 20 differentially expressed transcription factors were displayed in heatmap ( a ) and volcano plot ( b ). FC, fold change ( c ) Correlation analysis of the expressions of DCPS and STAT5B in GBMs in TCGA database. Statistical analysis by linear regression analysis ( d ) GBM cell lines were transfected with siRNA targeting DCPS for 48 h. The expression of STAT5B mRNA was analyzed by RT-qPCR and normalized to that of β-actin (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, **, p < 0.01, ***, p < 0.001 ( e ) GBM cell lines were treated with RG3039 (6 µM) or DMSO for 48 h. The expression of STAT5B mRNA was analyzed by RT-qPCR and normalized to that of β-actin (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, ****, p < 0.0001 ( f ) GBM cell lines were transfected with siRNA targeting DCPS for 48 h. The expressions of DCPS and STAT5B were analyzed by western blotting ( g ) GBM cell lines were treated with RG3039 (6 µM) or DMSO for 48 h. The expression of STAT5B was analyzed by western blotting

Article Snippet: To measure the growth of GBOs, similarly sized GBOs (0.5–1 mm diameter) were placed into individual wells of a 48-well tissue culture plate with 300 mL of GBO medium containing 10 µM RG3039 (HY-102020, MedChemExpress) or solvent (DMSO) per well.

Techniques: Inhibition, Expressing, Transfection, Quantitative RT-PCR, Western Blot

The anti-GBM effect of DCPS inhibition was mediated through reducing STAT5B expression ( a ) GBM cell lines with STAT5B overexpression or vector expression were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3) ( b ) Quantification of the ratio of Annexin-V-positive cells in apoptosis assays (see Figure b for details) in GBM cell lines with STAT5B overexpression or vector expression treated with RG3039 (6 µM) to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, **, p < 0.01, ***, p < 0.001 ( c ) Representative images of colony formation assays in GBM cell lines with STAT5B overexpression or vector expression treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells with STAT5B overexpression or vector treated with RG3039 to cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, ***, p < 0.001 ( e ) Schematic diagram summarizing that RG3039 inhibits DCPS regulating the expression of STAT5B, which plays an essential role in tumor progression

Journal: Journal of Translational Medicine

Article Title: Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma

doi: 10.1186/s12967-024-05658-x

Figure Lengend Snippet: The anti-GBM effect of DCPS inhibition was mediated through reducing STAT5B expression ( a ) GBM cell lines with STAT5B overexpression or vector expression were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay ( n = 3) ( b ) Quantification of the ratio of Annexin-V-positive cells in apoptosis assays (see Figure b for details) in GBM cell lines with STAT5B overexpression or vector expression treated with RG3039 (6 µM) to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, **, p < 0.01, ***, p < 0.001 ( c ) Representative images of colony formation assays in GBM cell lines with STAT5B overexpression or vector expression treated with various concentrations of RG3039 or DMSO for 14 days ( d ) Quantification of the ratio of colony formation of GBM cells with STAT5B overexpression or vector treated with RG3039 to cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, ***, p < 0.001 ( e ) Schematic diagram summarizing that RG3039 inhibits DCPS regulating the expression of STAT5B, which plays an essential role in tumor progression

Article Snippet: To measure the growth of GBOs, similarly sized GBOs (0.5–1 mm diameter) were placed into individual wells of a 48-well tissue culture plate with 300 mL of GBO medium containing 10 µM RG3039 (HY-102020, MedChemExpress) or solvent (DMSO) per well.

Techniques: Inhibition, Expressing, Over Expression, Plasmid Preparation, CCK-8 Assay